Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Rae

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Pharmacogenomics|January 23, 2016
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclinesDaniel L Hertz, Megan V Caram, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast CancersAndrea M Pesch, Nicole H Hirsh, Benjamin C Chandler, et al.
British Journal of Clinical Pharmacology|February 10, 2016
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226Daniel L Hertz, William E Barlow, Kelley M Kidwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2021
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 TrialCostanza Paoletti, William E Barlow, Erin F Cobain, et al.
Physiological Genomics|August 21, 2016
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumorsDaniel L Hertz, N Lynn Henry, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 TrialCorey W Speers, W Fraser Symmans, William E Barlow, et al.
Breast Cancer Research and Treatment|October 2, 2014
Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcomeKatherine Drews-Elger, Elizabeth Iorns, Alexandra Dias, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Pharmacogenomics|January 23, 2016
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclinesDaniel L Hertz, Megan V Caram, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast CancersAndrea M Pesch, Nicole H Hirsh, Benjamin C Chandler, et al.
British Journal of Clinical Pharmacology|February 10, 2016
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226Daniel L Hertz, William E Barlow, Kelley M Kidwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2021
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 TrialCostanza Paoletti, William E Barlow, Erin F Cobain, et al.
Physiological Genomics|August 21, 2016
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumorsDaniel L Hertz, N Lynn Henry, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 TrialCorey W Speers, W Fraser Symmans, William E Barlow, et al.
Breast Cancer Research and Treatment|October 2, 2014
Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcomeKatherine Drews-Elger, Elizabeth Iorns, Alexandra Dias, et al.
Pageof 13